Xu Binghe, Seidman Andrew, Chan Stephen
Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Oncologist. 2015 Jan;20(1):88. doi: 10.1634/theoncologist.2014-0284.
Many factors contribute to patient survival in metastatic breast cancer and other late-stage cancers. It is doubtful that adjuvant therapy causes a worse survival outcome. This being said, should resistance develop following adjuvant therapy, the patient needs to be offered a first-line solution that is free of cross-resistance.
许多因素影响转移性乳腺癌和其他晚期癌症患者的生存。辅助治疗导致更差生存结果的说法值得怀疑。话虽如此，如果辅助治疗后出现耐药，需要为患者提供一线无交叉耐药的治疗方案。
